This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Quality of Life  • Genetic Disorders  • Neuromuscular diseases  • Pain  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the article by Teunissen et al¹ in which the evolution of Charcot-Marie-Tooth disease type 2 (CMT2) was thoroughly quantified by examining a cohort of 43 patients during a 5-year period. Some points deserve further comment and elucidation. As indicated by the authors, CMT2 is genetically heterogeneous, but genetic characterization is only partially possible; therefore, it is likely that the conclusions of this study will have to be reconsidered in light of new information about the CMT2 gene, possibly defining different modes of the disease course for different genotypes. It would be interesting to know if specific clinical features were associated with slower or faster deterioration, as a possible clue to suspect different genotypes.

Another factor potentially interfering with the course of CMT2 is the coexistence of other diseases that can induce nerve damage. The authors do not specify if any of the patients had comorbidity . . . [Full Text of this Article]

Franco Gemignani, MD; Adriana Marbini, BSc

RELATED ARTICLE

Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply
Laurien L. Teunissen, Nicolette C. Notermans, Hessel Franssen, Baziel G. M. van Engelen, Frank Baas, and John H. J. Wokke
Arch Neurol. 2004;61(9):1470.
EXTRACT | FULL TEXT